REG - Allergy Therapeutics - Annual Report and Accounts Delayed

Allergy TherapeuticsAnnouncement

15/12/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231215:nRSO0237Xa&default-theme=true

RNS Number : 0237X  Allergy Therapeutics PLC  15 December 2023

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Publication of Annual Report and Accounts Delayed

Temporary Suspension of Shares

 

15 December 2023 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, announces
that its auditor, BDO LLP ("BDO"), has informed the Company that it requires
additional time to complete its audit for the year ended 30 June 2023, due
to resource availability within the audit engagement team.

 

As a result of the delay to the audit process, the Company will not meet the
deadline to publish its annual report and accounts by 31 December 2023.
Consequently, the Company is not able to comply with the requirements of AIM
Rule 19 of the AIM Rules for Companies which requires publication of the
Company's annual report and accounts within six months of the year end.
Accordingly, the Company's ordinary shares will be suspended from trading on
AIM with effect from 7.30 a.m. on 2 January 2024.

 

The Company's ordinary shares will remain temporarily suspended from trading
on AIM until such time as the Company has satisfied the requirements of AIM
Rule 19 with respect to publication of its annual report and accounts. The
final audit and subsequent publication of Allergy Therapeutics' annual report
and accounts are aiming to be completed as soon as possible, this is
anticipated to occur by the end of January 2024.

 

For further information on the Company, please visit the website:
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulations.

 

-  ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

ICR Consilium

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFLFSFFRLELIV